Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1424Pancreatic Neoplasms 851Carcinoma, Hepatocellular 743Stomach Neoplasms 640Colonic Neoplasms 439Rectal Neoplasms 401Esophageal Neoplasms 393Carcinoma, Non-Small-Cell Lung 328Breast Neoplasms 328Neoplasms 304Liver Neoplasms 280Cholangiocarcinoma 246Ovarian Neoplasms 242Lung Neoplasms 240Neoplasm Metastasis 237Gastrointestinal Neoplasms 217Melanoma 186Prostatic Neoplasms 164Biliary Tract Neoplasms 161Esophageal Squamous Cell Carcinoma 160Endometrial Neoplasms 143Uterine Cervical Neoplasms 128Squamous Cell Carcinoma of Head and Neck 128Carcinoma, Renal Cell 115Head and Neck Neoplasms 113Sarcoma 100Urinary Bladder Neoplasms 95Adenocarcinoma Of Esophagus 89Triple Negative Breast Neoplasms 84Anus Neoplasms 82

Interventions

tislelizumab 1Oxaliplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mid-low Rectal Cancer × Gastrointestinal × 1 year × Clear all
NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Completed
38 enrolled
Gastrointestinal

Mid-low Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡